Aweb-based UK register of biological and conventional therapy for psoriasis was set up in September 2007 by the British Association of Dermatologists (BAD), with the aim of assessing the long-term safety of biologics prescribed for severe disease.
The BAD Biologic Interventions Register is a prospective observational cohort study currently involving more than 3,000 patients, with around two-thirds receiving biologics and the rest (controls), conventional therapies.
The register will run for five years and has engaged clinical dermatologists and nurses from dermatology centres. Primary study endpoints include malignancy, infection, serious adverse events and death. Collection of long-term effectiveness data is a subsidiary aim.
Burden AD, Warren RB, Kleyn CE et al. Br J Dermatol 2012; 166(3): 545-54